The unrest in Syria has resulted in an escalating refugee crisis. The postwar lack of health care infrastructure in Iraq has also resulted in Iraqis seeking health care in neighboring countries. Pediatric cancer is largely curable, although its treatment is expensive and complex. Strategies to implement pediatric cancer care with curative intent in these vulnerable populations are lacking. METHODS: To assess the feasibility of a collaborative approach for the provision of care to displaced children with cancer, this study reviewed the experience of the authors over the past 6 years in Lebanon, the country with the highest number of refugees per capita in the world. RESULTS: The
INTRODUCTION
Lebanon, a country with a population of approximately 5 million, is located on the eastern coast of the Mediterranean Sea and is bounded by Syria in the north and the east. Since the 1970s, Lebanon has endured wars and political instability, which have contributed to a devastated infrastructure, a high national debt, and a relatively inflated cost of living. 1, 2 Although listed as a country with an upper-to middle-income economy by the World Bank, 28.6% of the population lives in poverty, and the total expenditure per capita for health care is $987; this constitutes approximately 6.4% of the gross domestic product. 3 More than 65% of Lebanese individuals depend on national health care plans, but these are frequently suboptimal for the treatment of chronic conditions such as cancer. [4] [5] [6] Despite health insurance disparities, all Lebanese nationals have some form of financial health care coverage, with the national governmental health care plan ensuring access to all governmental and many private hospitals. 7 Since the start of the war in Syria in 2011, the escalation of violence has resulted in an increase in the population of displaced Syrians in Lebanon. The documented number of refugees reached 1.5 million in 2015, with an additional unclear number of undocumented refugees. The government of Lebanon instructed the United Nations High Commissioner for Refugees (UNHCR) to suspend new registrations on May 6, 2015, and this makes the estimation of the total refugee population difficult. The global humanitarian response to the Syrian crisis by governmental and nongovernmental agencies has focused mostly on the support of basic needs, [8] [9] [10] [11] and funding for the treatment of noncommunicable diseases has been largely nonexistent. Displaced children with cancer in Lebanon have no means of support by any governmental or third-party entity, and most lack the personal finances to enable access to cancer therapy, with the exception of limited support from a few small nongovernmental organizations (NGOs). The UNHCR reports that, of the currently registered 1,011,366 displaced Syrians in Lebanon, 54.8% are under the age of 18 years, with the caveats of no refugee registration since May 2015, as mentioned previously, and a rising number of new births. 12, 13 Thus, a conservative estimate of childhood cancer cases among this population, with a presumed incidence of approximately 17 cases per 100,000 children, 14 15 On average, the AUBMC/CCCL provides full treatment for 72 Lebanese children with newly diagnosed cancer per year, regardless of their ability to pay. Fundraising efforts by the CCCL provide financial coverage for needed therapies. In addition, on average, 39 and 90 patients per year treated elsewhere in Lebanon receive specific procedures/diagnostic tests and consultations/opinions, respectively, at the AUBMC/CCCL.
Since 2011, the AUBMC/CCCL has been faced with the challenge of accommodating a continually rising number of non-Lebanese children with cancer seeking therapy. These patients consist primarily of displaced Syrians and Palestinians living in Lebanon as well as Syrians and Iraqis who have travelled from their home countries to Beirut specifically for medical care because of a lack of medical resources locally. These economically deprived populations have limited to absent financial resources or third-party health coverage, and this made it necessary for the AUBMC/CCCL and St. Jude/ALSAC to implement urgent actions to enable access to the same treatment and likelihood for a cure available to Lebanese children.
Here, we describe the efforts, prioritization scheme, mechanisms of support, and outcomes of patients receiving such care. Our report yields insight into the scope of the humanitarian refugee crisis in Lebanon as it pertains to childhood cancer. It also highlights the need for additional support for non-Lebanese children-primarily Syrian, Iraqi, and Palestinian-who are forced to seek care within Lebanon.
MATERIALS AND METHODS

Patient Population
The CCI at the AUBMC in Beirut, Lebanon, is a tertiary pediatric cancer center at which cancer treatment expenses for all children are financially covered by the CCCL, so no family pays out of pocket, while they are receiving standard-of-care multidisciplinary treatment for childhood cancer. Because all Lebanese patients benefit from at least partial health care coverage through national health care plans, a significant part of the cost of their treatment is defrayed. Since 2011, there has been a significant rise in the numbers of non-Lebanese patients seeking care at the CCI due to the increasing Syrian refugee population within Lebanon as well as the influx of nonrefugee Syrian and Iraqi patients from Syria and Iraq seeking cancer care because of a lack of medical infrastructure locally in the war-torn and postwar devastated environments, respectively. The high cost of cancer care, the lack of financial means among these families, and the absence of third-party health care coverage for these patients have threatened the viability of local resources even as providers face the moral obligation of treating children with a diagnosis of curable cancer.
Fund Development and Resource Planning
2011-2013, CCCL and NGO funds
During the early period of the crisis in Syria, the CCCL covered the costs for the care of displaced children with cancer in Lebanon treated at the AUBMC. A few NGOs contributed funds for the treatment of these displaced children. The criteria for accepting and providing care at the CCI were the same as those for Lebanese children. Specifically, patients had to have a new diagnosis with no prior treatment and be younger than 18 years. Acceptance was contingent on the availability of funds within the CCCL's yearly budget.
2013-2016, Humanitarian Fund 1 (HF1)
In 2012, because of the increasing number of nonLebanese children with cancer in need of treatment and the lack of financial support, the CCCL sought help from St. Jude/ALSAC. HF1 was initiated in May 2013. It aimed to provide a variety of assistance mechanisms over a 2-year period, including full treatment for a fixed number of patients and partial assistance, such as surgery, radiation therapy, or induction chemotherapy, for another subset of patients. All non-Lebanese pediatric patients with newly diagnosed cancer were eligible.
2014-2017, Humanitarian Fund 2 (HF2)
Once the HF1 funds were depleted, HF2 was applied to cover a 3-year period (October 2014 to September 2017).
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Cancer April 1, 2018 To ensure that the available funds could assist as many patients as possible while curative outcomes were maintained, additional eligibility criteria were established. Only patients with a documented refugee status and newly diagnosed, curable cancer were eligible. Because of cost-benefit constraints, bone marrow transplantation was excluded. Enrollment decisions were made on a case-bycase basis, and the cost of each patient's treatment plan was projected at the time of acceptance to ensure the availability of funds for full treatment. Actual costs were computed on a monthly basis, and budget projections were adjusted accordingly. Plans for future acceptances were also adjusted according to the actual budget to ensure that the program remained within total projected expenditures.
2012-2017, disease-specific programs
Funds that were not assigned for humanitarian purposes but were designed for the collaborative treatment of Lebanese children throughout Lebanon were also made accessible for the enrollment of non-Lebanese patients. 16 These disease-specific programs allowed collaborative interactions among community pediatric oncologists and the CCI to enable patients treated at other hospitals to have access to multidisciplinary planning and to enroll into common, nationwide, standard-of-care treatment plans. The disease-specific programs were also supported by a financial partnership between St. Jude/ALSAC and the AUBMC/CCCL. All nationalities were eligible for enrollment. As before, patients had to have newly diagnosed cancer, and a centralized review of diagnostic studies and staging, a commitment to complete treatment according to a common, standard-of-care, disease-specific treatment plan, centralized local control at the CCI (when applicable), and provision of follow-up information were required.
Data Collection
All patients enrolled in the aforementioned programs had initial demographic and clinical information recorded in a common database along with actual and projected budgets. Responses, outcomes, and follow-up information were collected prospectively for primary use in treatment planning, budgeting, the assurance of compliance with treatment, and the scheduling of follow-up surveillance studies. A coordinator for the programs was responsible for data collection, follow-up, and communication with physicians across hospitals.
Data Review and Analysis
Available information was collected until May 31, 2017. It included the number of patients referred, enrolled, or declined; respective diagnoses; types of treatment provided; costs of treatment; and most recently documented outcomes, including relapse and death events. Data were analyzed with Microsoft Excel. Categorical variables were summarized by the calculation of the means and percentages. The review and analysis were deemed by the AUBMC Institutional Review Board to be exempt research.
RESULTS
Patient Enrollment and Nationalities
Between January 1, 2011, and May 31, 2017, the CCI provided cancer care to 630 Lebanese patients (508 received full treatment and 122 received partial support for specific diagnostic or therapeutic procedures), with another 239 Lebanese patients receiving consultations/ opinions only. During this period, care was also provided for 311 non-Lebanese patients (107 received full treatment, and 204 received partial treatment), and an additional 264 patients received consultations/opinions only (Fig. 1A) . Figure 1B shows the distribution of nonLebanese patients accepted via the different funding programs, by year, with the total number of patients assisted per year as well as the total number of those who were declined because of either a lack of eligibility or unavailable funds and, therefore, received only consultation. The percentage of non-Lebanese patients accepted for treatment at the CCI was 18% at the beginning of the crisis in 2011, and it increased progressively to stabilize at 55% to 60% from 2015 to the date of this report (Fig. 1B, lower  panel) .
Between January 2011 and June 2013, the number of non-Lebanese patients treated at the CCI gradually increased (from 9% to 32% of total patients; Fig. 2A ), and this reflected the increased influx of refugees into Lebanon, as reported by the UNHCR. The vast proportion of non-Lebanese patients (86%) were treated between May 2013 and May 2017; this included the period covered by the St. Jude/ALSAC humanitarian fund programs.
Of presenting non-Lebanese patients, 54% were accepted for treatment (19% for full therapy and 35% for specific procedures), whereas 72% of Lebanese patients were (58% for full therapy and 14% for specific procedures), as shown in Figure 1A . When they were analyzed by year and nationality, the majority of non-Lebanese patients seen after 2012 were Syrian (Fig. 2A) . Overall, 56% and 52% of Syrian and Palestinian patients, respectively, were accepted for treatment (whether full or partial), whereas 62% of Iraqi patients were given only an opinion (Fig. 2B ).
Fund Allocation, Treatment, and Outcomes
The HF1 program was aimed at covering the costs of care for displaced patients over a 2-year period (May 2013 to April 2015). HF1 sponsored full treatment for 27 patients, specific interventions (surgery, radiation, or induction chemotherapy) for 11 patients, and diagnostic evaluations for an additional 31 patients. However, the number of displaced patients receiving treatment at the CCI was continually increasing (Fig. 2) , with 49% of the total patients seen at CCI being displaced children during the 6-month period between July and December 2013 ( Fig. 2A) .
To maximize the benefits and ensure sustainability, modifications were made for the HF2 program, which specifically focused on patients with curable disease and excluded bone marrow transplantation. The HF2 program planned steady enrollment over a 3-year period (October 2014 to September 2017). It enrolled 48 patients during this time and did so at a steadier pace than HF1, and it maintained the proportion of displaced children treated at the AUBMC between 30% and 35% of the total patient population (Fig. 2A) .
The remaining patients who were not accepted for treatment via HF1 or HF2 were given a medical opinion and a treatment plan, and they were considered for enrollment into disease-specific funded programs. Displaced children who enrolled into the disease-specific programs were covered for diagnostic studies, local-control modalities (surgery and radiation therapy), and multidisciplinary treatment planning. Chemotherapy, when applicable, was administered at other hospitals in Lebanon. Small NGOs and charities helped to fund chemotherapy treatment at other hospitals for Syrian and Palestinian patients. To our knowledge, no directed funds or NGOs were available for Iraqi families outside the CCI, so they had to pay out of pocket at other hospitals; however, the diagnostic and local-control costs covered by our funds helped to alleviate some of the total cost. Patients treated in disease-specific programs are included in the partial-treatment category (Fig. 1B) . The numbers of patients according to cancer type and funding program are presented in Table 1 .
Treatment planning was not influenced by patient nationality, and all enrolled patients had access to curative and function-preserving procedures, such as limb-salvage surgery for bone tumors, intensity-modulated radiation therapy for solid and brain tumors, and examinations under anesthesia with focal laser therapy for retinoblastomas. The average costs of treatment at the CCI according to the diagnosis and scope of therapy are presented in Supporting Table 1 (see online supporting information).
Disease staging per diagnostic subgroup is detailed in Supporting Table 2 (see online supporting information), and it showed that 29% of the patients had high-risk disease (high-risk acute leukemia, metastatic solid tumor, We obtained follow-up information for all patients who had received treatment or were continuing on active first-line therapy. Of a total of 275 patients, 159 (58%) were in remission at the most recent follow-up, with an additional 56 (20%) continuing first-line treatment. In addition, 3 patients (1%) died of toxicity, 35 (13%) had relapse/disease progression, and 22 (8%) left before treatment completion. Only 5 of these 22 patients abandoned treatment, whereas 9 (8 Syrians and 1 Palestinian) relocated to another country where they were presumed to be continuing therapy, and 8 (all Iraqis) traveled back to their home country to continue treatment. The disease status follow-up for these patients was not available. Outcome details by disease subtype are shown in Table 2 .
Notably, of the 159 patients who finished treatment, 115 (72%) had been seen more than 1 year after the end of treatment, and of those patients, only 62 (39% of the total patients) had more than 2 years of follow-up information available. The remainder had shorter follow-up or had not provided further status information.
DISCUSSION
Syrian refugees live in more than 1700 communities and locations across Lebanon. By April 2014, more than 1 in 4 people in Lebanon were refugees, and they were overstretching the country's capacities and placing pressure on an already weakened economy. 8, 17 This population continues to grow because of the unresolved conflict in Syria and additional annual births exceeding 2000 Syrian infants within Lebanon. 18 Beyond access to basic services, many refugees have health care needs due to preexisting chronic conditions, injuries, and noncommunicable diseases. [19] [20] [21] [22] Although the UNHCR partially subsidizes primary health care for registered Syrian refugees, it is unable to cover costly chronic conditions because foreign aid is far lower than what is needed to respond to this crisis. 19, 23, 24 Childhood cancer is highly curable; however, the costs of treatment are beyond what displaced families can afford. The CCI currently treats an estimated 30% of all new Lebanese pediatric cancer cases in Lebanon (Fig. 3A) . Therefore, it is likely that the number of displaced children with cancer seeking care in Lebanon is higher than what has been captured in our report. Indeed, the areas of Lebanon with the largest number of displaced families are those in the periphery of the country, where there is a scarcity of hospitals with pediatric oncology specialists (Fig. 3B) . However, we suspect that because of the paucity of financial coverage elsewhere in the country, most non-Lebanese children are likely referred to our center for support. (12) 31 (10) 48 (15) 162 (52) 32 (10) There were no differences in treatment planning or allocation according to the refugee status, and all patient families verbalized a willingness to be treated for the whole duration of therapy. Indeed, patients who ended up relocating were provided with treatment summaries and detailed treatment plans to continue their therapy elsewhere. The long-term collaboration between the AUBMC/CCCL and the St. Jude/ALSAC partnership, on the one hand, and the established national pediatric oncology networks, on the other hand, were crucial for the success of this effort, and they have demonstrated the role that such networks can play in crisis situations. The low rate of abandonment demonstrates the ability of displaced families to complete intensive and long courses of cancer therapy if they are given adequate support. The preliminary patient outcomes are encouraging, with the caveats of the relatively short follow-up period (with 20% of the patients still on active treatment) and the small number of patients within each diagnosis subgroup, which preclude meaningful comparisons with expected outcomes.
Similar results were reported for 212 displaced children with cancer treated in Turkey. 26 Turkey has the third highest refugee burden after Lebanon and Jordan. Refugees constitute approximately 3.6% of the total population in Turkey, and their medical care is financially covered by the government. 27 The favorable outcomes strengthen the imperative to facilitate appropriate treatment for displaced children, many of whom would have received curative therapy in their home countries before the conflict. 28, 29 Indeed, some Syrians and Iraqis who left their countries in recent years were seeking medical treatment they could no longer obtain in their homeland. 30, 31 It is estimated that more than 2000 children in the Middle East will be affected by cancer in countries where previously adequate health care systems have collapsed. 32, 33 Our report demonstrates that providing care for this population is feasible through partnerships with committed centers and advocates.
There are very few published data regarding the management of the financial needs of cancer care in refugee populations. A few studies have attempted to characterize types of prevalent cancers and referral mechanisms in refugee settings, such as Afghan, 34 Nigerian, 35 and other refugee populations. 36 The UNHCR has attempted to address cancer care in refugees through the exceptional care committees, where applications for cancer treatment support were submitted and studied for eligibility. 37 Results reported in Syria and Jordan between 2009 and 2012 showed that 48% of applications were funded, and the major reason for application denial was a determination of a poor prognosis. Although 66% to 73% of approved applications received the full requested amount for treatment, no information was available regarding treatment planning or delivery details or patient outcomes. 37 Our reported initiative on the care of displaced children with cancer in Lebanon demonstrates that cooperative programs can positively affect the lives of such vulnerable patient populations. To continue the currently described efforts, the St. Jude/ALSAC-CCCL/AUBMC collaboration has now initiated a successor fund, Humanitarian Fund 3. However, more efforts from both private and public sectors are needed. Civil disturbances and past wars have challenged Lebanon's ability to balance the role of the public and private sectors in health care and to implement sustainable health care policies. The strong presence of the private sector, however, has ensured the sustainability of quality medical care under challenging situations. [38] [39] [40] [41] [42] [43] The scale of the current crisis, however, now calls for a scholarly global health strategy to address and advocate for the right of displaced populations to quality care.
Similar to this initiative in Lebanon, a collaboration for displaced children with cancer in Jordan, the country with the second highest number of refugees per capita, has recently been initiated by St. Jude/ALSAC. In addition, efforts are underway to form a task force that will include key stakeholders, social scientists, advocacy groups, and international agencies. This taskforce's aim will be to guide the implementation of regional solutions, help to garner global support to develop a coordinated program for displaced children with cancer in the Middle East, and establish a model for health care intervention in crises with displaced populations.
FUNDING SUPPORT
The American Lebanese Syrian Associated Charities and the Children's Cancer Center of Lebanon Foundation funded this study. 
